OmniAb (OABI) Liabilities and Shareholders Equity (2021 - 2026)
OmniAb (OABI) posted quarterly Liabilities and Shareholders Equity of $293.6 million for Q1 2026, down 4.09% year-over-year from $306.2 million in Q1 2025, and down 2.41% quarter-over-quarter from $300.9 million in Q4 2025.
OmniAb (OABI) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $293.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 4.09% year-over-year to $293.6 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 7.74% YoY), while the FY2025 annual figure was $300.9 million, down 7.57% from the prior year.
- Liabilities and Shareholders Equity retreated to $293.6 million in Q1 2026 per OABI's latest filing, from $300.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $421.2 million in Q4 2022 and bottomed at $236.8 million in Q2 2022.
- Historically, Liabilities and Shareholders Equity has averaged $327.7 million across 5 years, with a median of $325.6 million in 2024.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 37283.13% — and 2024, when it retreated 16.77%.
- OmniAb's Liabilities and Shareholders Equity stood at $421.2 million in 2022, then decreased by 10.92% to $375.2 million in 2023, then fell by 13.24% to $325.6 million in 2024, then fell by 7.57% to $300.9 million in 2025, then dropped by 2.41% to $293.6 million in 2026.
- Business Quant data shows OABI's Liabilities and Shareholders Equity at $293.6 million in Q1 2026, $300.9 million in Q4 2025, and $309.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 290.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 290.26 Mn |
| Mar 31, 2026 | 293.65 Mn |
| Dec 31, 2025 | 300.91 Mn |
| Sep 30, 2025 | 309.69 Mn |
| Jun 30, 2025 | 295.67 Mn |
| Mar 31, 2025 | 306.18 Mn |
| Dec 31, 2024 | 325.56 Mn |
| Sep 30, 2024 | 331.55 Mn |
| Jun 30, 2024 | 337.26 Mn |
| Mar 31, 2024 | 352.56 Mn |
| Dec 31, 2023 | 375.23 Mn |
| Sep 30, 2023 | 391.71 Mn |
| Jun 30, 2023 | 405.24 Mn |
| Mar 31, 2023 | 413.04 Mn |
| Dec 31, 2022 | 421.21 Mn |
| Sep 30, 2022 | 237.61 Mn |
| Jun 30, 2022 | 236.79 Mn |
| Mar 31, 2022 | 236.90 Mn |
| Dec 31, 2021 | 304.47 Mn |
| Sep 30, 2021 | 236.99 Mn |